{
  "docId": "019de076-341d-707d-8f10-e094a3d9771c",
  "docSlug": "c0c2a81b97260bf20014943df2470872",
  "documentTitle": "Equillium | Investor Presentation Deck | 39 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 38,
  "pageCount": 39,
  "prevPage": 37,
  "nextPage": 39,
  "slideType": "timeline",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a grouped list format to present clinical trial milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-341d-707d-8f10-e094a3d9771c/38",
  "deckHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c",
  "deckJsonHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json",
  "deckAnchorHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-38",
  "components": [
    {
      "bbox": {
        "h": 0.135,
        "w": 1,
        "x": 0,
        "y": 0.745
      },
      "kind": "callout",
      "text": "Cash runway expected to extend into 2025*. Potential Ono Exercise Payment of ~$33M** would significantly extend cash runway",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee01e8d1-f459-495d-a0f6-d272d1f341d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.48,
        "w": 0.926,
        "x": 0.037,
        "y": 0.22
      },
      "kind": "list",
      "text": "EQ101 – Phase 2 Clinical Study: Alopecia Areata – Initial Data (Q4 2023), Alopecia Areata – Topline Data (Mid-2024). EQ102 – Phase 1 Clinical Study: SAD / MAD (healthy volunteers) – Data (Q4 2023), Celiac Disease – Data (2024). Itolizumab – Phase 1b / Phase 3 Clinical Studies: Lupus Nephritis EQUALISE Study (Phase 1b) – Topline Data (Early 2024), aGVHD EQUATOR Study (Phase 3) – Interim Review (2024).",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f185bc9a-eef3-4432-b7be-40cdbd34b124",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.737,
        "x": 0.163,
        "y": 0.965
      },
      "kind": "source-note",
      "text": "* Estimated based on current operating plan ** Option exercise payment of ¥5.0B is based in JPY and subject to currency exchange rate at the time of payment",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae5e02ae-dd38-450b-8c3e-611f86214849",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.048,
        "w": 0.178,
        "x": 0.037,
        "y": 0.075
      },
      "kind": "title",
      "text": "Milestones",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "53d40daa-5ed8-4a91-adbd-e457454f4344",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "90d482f5-91f1-44d5-a093-41850816053a",
      "evidence": "The slide presents a timeline of clinical milestones for multiple programs.",
      "confidence": 0.7
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}